TD Cowen维持对Moderna股票(NASDAQ: MRNA)的"持有"评级，目标价保持在60.00美元不变。 该公司在生物科技板块第三季度财报预览前发布了这一更新，并对Moderna的财务模型进行了调整。

The biotech industry is buzzing with exciting changes, and a lot of it is thanks to one company: Moderna. Known for its COVID ...

In recent years, the biotech industry has seen a lot of exciting changes, and much of that is thanks to one company: Moderna.

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

作者：黄莺美国Moderna公司的专利官司持续不断。一周前，2024年10月12日，葛兰素史克公司（GSK）向美国特拉华州地方法院起诉Moderna，指控其COVID-19疫苗Spikevax以及今年5月份获得FDA批准的RNA呼吸道合胞病毒(RSV ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own ...

作者：黄莺俗话说人红是非多。在新冠疫情期间，凭借mRNA疫苗大获成功的Moderna公司，从年营收只有几千万美元的公司，一举跨入年营收200亿美元的公司行列。而这为其也带来了越来越多的专利纠纷。2021年，Moderna与美国国立卫生研究院的mRNA ...

在充满挑战的市场环境中，Moderna Inc. (MRNA)股价已触及52周低点，跌至57.71美元。这家以mRNA疫苗闻名的生物技术公司在过去一年经历了动荡，其股价反映出显著下滑。过去一年，Moderna股价下跌了42.71%，表明投资者情绪看空 ...